Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on BioCryst (BCRX – Research Report) today. The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector, ...

BioCryst ( (BCRX) ) has issued an announcement. BioCryst Pharmaceuticals reported a strong Q3 2024 with ORLADEYO net revenue of $116.3 million, growing 35.7% year-over-year, and adjusted full-year ...

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on BioCryst (BCRX – Research Report), with a price ...

The drugmaker posted revenue of $117.1 million in the period, surpassing Street forecasts. Three analysts surveyed by Zacks expected $114.8 million. BioCryst expects full-year revenue in the range of ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Monday reported a loss of $14 million in its third quarter. The Durham, North Carolina-based company said it had ...

BioCryst expects full-year revenue in the range of $443 million to $448 million. BioCryst shares have risen 41% since the beginning of the year. The stock has climbed 49% in the last 12 months.